Jan 23, 2026 02:10PM Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds

Jan 21, 2026 08:31AM Revelation Biosciences reaches FDA agreement on drug approval pathway

Jan 21, 2026 08:30AM Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI

Jan 14, 2026 09:00AM Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

Jan 12, 2026 05:00PM Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 7, 2026 09:03AM Revelation Biosciences begins GMP manufacturing of GEMINI drug and placebo

Jan 7, 2026 09:00AM Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

Dec 1, 2025 09:00AM Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting

Nov 20, 2025 09:01AM Revelation Biosciences schedules FDA meeting for Gemini kidney treatment

Nov 20, 2025 09:00AM Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

Nov 6, 2025 04:15PM Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

Oct 29, 2025 09:00AM Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

Oct 15, 2025 05:00PM Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

Sep 30, 2025 06:05AM Revelation Biosciences (REVB) files for 13.07M share offering by selling stockholders

Sep 11, 2025 08:32AM Revelation Biosciences raises $9.6 million through warrant exercise

Sep 11, 2025 08:30AM Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

Sep 10, 2025 07:23AM Revelation Biosciences reports positive phase 1b CKD trial data

Sep 10, 2025 07:20AM Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

Sep 9, 2025 04:56PM Revelation Biosciences schedules webcast to discuss Phase 1b data

Sep 9, 2025 04:55PM Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

Sep 9, 2025 08:14AM Revelation Biosciences reports positive phase 1b study results for CKD drug

Sep 9, 2025 08:00AM Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

Jul 1, 2025 05:26PM Revelation Biosciences (REVB) announces 1-for-3 reverse stock split

May 29, 2025 08:01AM Revelation Biosciences (REVB) Prices 3.64M Share Offering at $1.10/sh

May 23, 2025 04:07PM Revelation Biosciences (REVB) announces Board retirement

May 9, 2025 07:08AM Revelation Biosciences (REVB) Misses Q1 EPS by 211c

Jan 24, 2025 06:05AM Revelation Biosciences (REVB) Announces 1:16 Reverse Share Split

Dec 19, 2024 04:19PM Revelation Biosciences (REVB) Files for 14.22M Share Offering by Selling Stockholders

Dec 3, 2024 08:38AM Revelation Biosciences (REVB) Announces Exercise of Warrants for $4 Million in Gross Proceeds

Dec 2, 2024 06:00AM Revelation Biosciences (REVB) Announces FDA Acceptance of Gemini IND

Sep 3, 2024 05:12PM Revelation Biosciences (REVB) Files for 5.1M Share Offering by Selling Stockholders

Jul 19, 2024 04:04PM Revelation Biosciences (REVB) Files $50M Mixed Shelf

Jun 25, 2024 05:09AM Roth/MKM Reiterates Buy Rating on Revere Bank (REVB)

Jun 24, 2024 09:02AM Revelation Biosciences (REVB) Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity